Table 2

Unadjusted and adjusted analyses of impact of mesalamine/sulfasalazine on risk of severe COVID-19 in the Danish COVID-IBD cohort

Medication comparison	OR (95% CI)	P value	aOR (95% CI)	P value
Risk of severe COVID-19
5-ASA
Ref=no treatment with 5-ASA*	1.68 (0.56 to 5.06)	0.34	1.56 (0.44 to 5.81)	0.49
Risk of COVID-19 requiring hospitalisation
5-ASA
Ref=no treatment	1.02 (0.54 to 1.89)	0.96	0.91 (0.43 to 1.88)	0.79
Ref=mono-biological therapy	1.68 (0.58 to 6.07)	0.38	1.42 (0.32 to 8.25)	0.67
Ref=TNF mono†	2.14 (0.57 to 14.04)	0.33	0.91 (0.15 to 8.17)	0.92
5-ASA monotherapy
Ref=no treatment	0.53 (0.12 to 1.58)	0.32	0.50 (0.10 to 1.72)	0.32
Ref=mono-biological therapy	0.93 (0.17 to 4.55)	0.93	0.73 (0.08 to 7.32)	0.78
Ref=TNF mono†	0.50 (0.10 to 1.72)	0.32	0.45 (0.15 to 1.70)	0.31
High-dose 5-ASA (ref=low dose)‡	1.23 (0.26 to 4.35)	0.77	0.65 (0.07 to 3.91)	0.67

Adjusted p value using Bonferroni correction method.
*Model adjusted for age, sex, race (black vs non-Hispanic white, Asian vs non-Hispanic white), Hispanic versus non-Hispanic, disease type, disease activity, cardiovascular disease, corticosteroids, TNF antagonist, thiopurine, diabetes, lung disease and cancer.
†Model adjusted for age, sex, race (Asian vs non-Asian), disease type, disease activity, cardiovascular disease and corticosteroids.
‡Model adjusted for age, sex, race (white vs non-white), disease type, disease activity, cardiovascular disease, corticosteroids, combination therapy and thiopurine monotherapy.
aOR, adjusted OR; 5-ASA, 5-aminosalicylates; TNF, tumour necrosis factor.